IL1B and gout: No injection site reactions, hypersensitivity, or infectious complications were observed throughout the entire follow-up period.<h4>Conclusions</h4>IL-1β blockade Firsekibart may represent a safe and effective option for managing acute gout attacks in high-risk ESRD patients on PD with multiple comorbidities.